Cardiology

Trends show e-cigarette use in patients with CVD decreased from 2015 to 2019, but rebounded in 2019, potentially owing to the COVID-19 pandemic.

Michelle M. Kittleson, MD, PhD, and James Januzzi, MD, review signs that point to oHCM, highlighting family history and details on the diagnostic evaluation.

Andrew Wang, MD, outlines the epidemiology of obstructive hypertrophic cardiomyopathy (oHCM), and Milind Desai, MD, MBA, reviews the etiology of the condition.

A multi-center study in France found recreational drug use was independently associated with the occurrence of in-hospital outcomes.

A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.

In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

Health data from more than 50,000 adults revealed racial differences in cardiovascular mortality disappeared after adjusting for social risk factors.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.

Last week, the FDA authorized marketing for Viz.AI’s Viz HCM, a standalone ECG analysis software to identify adult patients for further follow-up for hypertrophic cardiomyopathy.

Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.

This cardiology case report features a woman in her mid 40s reporting chest pain and palpitations. Check out the ECG and determine the most likely rhythm in this patient!

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

A protein targeted by some marketed lipid-lowering agents may increase risk of developing irritable bowel disease.

An analysis of data from more than 80,000 patients using statins suggests the initial benefit on LDL-C reduction was greater for older patients than younger patients.

This cardiology case report from Brady Pregerson, MD, features a patient in their late 60s presenting with multiple episodes of chest pain. Check out the ECG and determine the correct diagnosis!

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

A cross-sectional analysis of more than 100 countries and regions revealed a statistically significant association between the prevalence of daily soft drink consumption and the prevalence of overweight and obesity.

The FDA has announced Abiomed has initiated a recall of all left-sided Impella pumps, citing inadequate instructions for use as it pertains to precautions to take with patients who have undergone TAVR.

A new scientific statement indicates lifestyle interventions may change the trajectory of obesity-related cardiovascular risk from onset in childhood to manifestation in adulthood.

A secondary analysis of ASPREE is bringing the role of aspirin in primary prevention settings further into question, suggesting daily use of low-dose aspirin was associated with a 38% increase in intracranial bleeding in older adults.

A study from Denmark leveraging more than 40 million years of follow-up data from patients dating back to the 1950s offers insight into the apparent increase in the risk of myocardial infarction associated with pregnancy loss in women and whether this same effect is observed in male partners.